Tenaya Therapeutics Plunges 40% Amid Public Offering and Layoffs

Introduction

Tenaya Therapeutics Inc. (Nasdaq: TNYA) is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2016 by scientists from the David J. Gladstone Institutes and the University of Texas Southwestern Medical Center, Tenaya focuses on developing gene and cell-based therapies that target the genetic causes of heart disease.

Corporate Structure and Workforce

As of its 2024 annual report, Tenaya employed 97 full-time staff across research, manufacturing, and administrative functions. On LinkedIn, the company is listed as having between 51 and 200 employees. Tenaya maintains a manufacturing facility in California, which is expected to become inactive later in 2025, although the company will retain ownership of the site.

Gene therapy by Sangharsh Lohakare

Recent Developments and News

• December 11, 2025 – Tenaya announced the pricing of a public offering of common stock and concurrently proposed an additional public offering. The proceeds are intended to fund its clinical-stage gene therapy programs.
• Throughout 2025 – Tenaya initiated a restructuring plan that will affect 30% to 40% of its workforce, primarily in research and manufacturing. The company expects the program to incur charges between $1.6 million to $2.7 million, largely for severance and benefits, while aiming to significantly reduce cash burn through mid-2026.
• March 2025 – At the American College of Cardiology Annual Meeting, Tenaya presented initial Phase 1b/2 (MyPEAK™-1) data for TN-201, its adeno-associated virus (AAV)-based therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM). In the first three patients, the therapy demonstrated transduction, a 13-fold increase in MYBPC3 RNA, and increases in myosin-binding protein C levels.
• November 2025 – In its RIDGE™-1 Phase 1b trial of TN-401 for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), Tenaya reported that TN-401 was generally well tolerated, increased PKP2 protein expression, and showed reductions in arrhythmia burden in patients with more than six months of follow-up.

Financial and Strategic Analysis

Tenaya’s stock price has decreased by 40.42% to $0.8103, with a trading volume of 27.27 million shares on the Nasdaq. The company does not have marketed products and relies on equity financing and partnerships for its operations. The public offering announced on December 11 is expected to strengthen its balance sheet, while the workforce reduction is aimed at extending its cash runway into the second half of 2026. Key strategic assets include:

• TN-201: Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the U.S. Food and Drug Administration; orphan medicinal product designation in Europe.
• TN-401: Fast Track and Orphan Drug designations from the FDA; orphan medicinal product designation in Europe.
• TN-301: A preclinical small-molecule HDAC6 inhibitor for heart failure with preserved ejection fraction (HFpEF), identified using Tenaya’s Precision Medicine platform.

Market Position and Industry Context

Tenaya operates within the cardiac gene therapy sector, focusing on sub-populations of patients with genetic cardiomyopathies. MYBPC3 mutations account for an estimated 120,000 cases of HCM in the U.S., while PKP2 mutations comprise over 40% of ARVC cases, impacting approximately 70,000 people. The company competes with other gene therapy developers and academic institutions engaged in in vivo cardiac gene delivery. Its emphasis on molecularly defined patient groups and one-time intravenous infusions aligns with industry trends toward precision medicine and durable, disease-modifying treatments.

tl;dr

Tenaya Therapeutics’ stock price has decreased by 40.42% to $0.8103 amid a 30% to 40% workforce reduction planned for throughout 2025. On December 11, the company priced a public offering to fund its lead gene therapy programs, aiming to extend its cash runway into the second half of 2026. Clinical results reported this year indicated dose-dependent increases in target proteins for TN-201 (HCM) and early safety and efficacy signals for TN-401 (ARVC). Additional readouts from the RIDGE-1 trial are expected in Q4 2025, along with ongoing enrollment milestones for MyPEAK-1.